title: Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?
authors.affiliation: Kennedy Institute of Rheumatology and University of Oxford, Oxford, UK.
authors.forename: Marc
authors.initials: M
authors.lastname: Feldmann
authors.affiliation: Kennedy Institute of Rheumatology and University of Oxford, Oxford, UK.
authors.forename: Ravinder N
authors.initials: RN
authors.lastname: Maini
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D055808:Drug Discovery / Q000639:trends; D004359:Drug Therapy, Combination; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy / Q000639:trends; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000037:antagonists & inhibitors*; D012219:Rheumatology / Q000639:trends; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D018501:Antirheumatic Agents; D020381:Interleukin-17; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha